Author

Synat Kang

Observed name: Kang, Synat

Institutions: Shenzhen University, Shenzhen University Health Science Center

Observed institutions: Guangxi Minzu University, Shenzhen University, Chinese Academy of Sciences, Guangzhou Institutes of Biomedicine and Health, Shenzhen University Health Science Center, State Key Laboratory of Respiratory Disease, University of Chinese Academy of Sciences

ORCID: 0000-0001-6898-5289

Observed ORCID: 0000-0001-6898-5289

OpenAlex ID: A5070021990

The Advances and Challenges of NK Cell-Based Cancer Immunotherapy

2021 · Synat Kang, Xuefeng Gao, et al. · Current Oncology · 50

Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges

2022 · Synat Kang, Yisheng Li, et al. · Frontiers in Oncology · 25

Differential Regulation of chTLR3 by Infectious Bursal Disease Viruses with Different Virulence In Vitro and In Vivo

2017 · Xiumiao He, Yanyan Chen, et al. · Viral Immunology · 19

Systemic tumor regression with synergy therapy: radiotherapy and CAR-T

2024 · Xingyu Ma, Wei Zhang, et al. · Cell Death Discovery · 18

Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype

2022 · Synat Kang, Lixin Wang, et al. · Oncogene · 18

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

2019 · Synat Kang, Yanyan Li, et al. · Frontiers of Medicine · 6

Epigenetic silencing of UBXN8 contributes to leukemogenesis in t(8;21) acute myeloid leukemia

2021 · Erna Yang, Wei Guan, et al. · Experimental & Molecular Medicine · 3

Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory-like phenotype

2022 · Kang, Synat, Gao, Xuefeng, et al. · Figshare

Works count: 8

Citation count: 139

H-index: 6

I10-index: 5